Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,681.12
(
-0.52%
)
US TECH 100
24,037.60
(
-0.39%
)
Dow Jones
46,600.70
(
-0.84%
)
Brent Oil
105.45
(
4.77%
)
Bitcoin
71,254.96
(
-3.64%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 35819

Thursday, 10/18/2007 5:07:21 PM

Thursday, October 18, 2007 5:07:21 PM

Post# of 257253
Yet another glitch with an HCV polymerase inhibitor: GS9190, a non-nuke from GILD, has run into QTc-prolongation issues and will need another phase-1 dose-escalataion study before phase-2 can begin. At the least, the GS9190 program has been pushed back about half a year. (Source: Today’s GILD CC)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now